(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/182857 A1

(51) International Patent Classification:
A61K 31/437 (2006.01) *A61K 31/519* (2006.01)
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/017678

(22) International Filing Date:
24 February 2022 (24.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21382163.0	25 February 2021 (25.02.2021)	EP
63/232,866	13 August 2021 (13.08.2021)	US
63/297,098	06 January 2022 (06.01.2022)	US

(71) Applicant: **IMPACT BIOMEDICINES, INC.** [US/US]; 86 Morris Avenue, Summit, New Jersey 07901 (US).

(72) Inventors: **ARONCHIK, Ida**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **BELTRAN VALENCIA, Roxxana Valeria**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **CARRANCIO ANTON, Maria Soraya**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **CHANG, Henry H.**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **COKER, Shodeinde**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **DAS, Sharmila**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **FILVAROFF, Ellen Hope**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **GUARINOS MARHUENDA, Carla**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **HANNA, Bishoy**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **LIU, Yu**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **NIKOLOVA, Zariana**; c/o Impact Biomedicines, Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US). **ESPOSITO, Oriana**; Via Collina D'Oro, 78 Montagnola, 6926 Ticino (CH).

(74) Agent: **COVERT, John M.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: USE OF A BET INHIBITOR ALONE OR IN COMBINATION WITH FEDRATINIB OR RUXOLITINIB FOR TREATING A HEMATOLOGICAL MALIGNANCY SUCH AS MYELOFIBROSIS

(57) Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer.

WO 2022/182857 A1